Evaluation
*
HighAbove AverageAverageBelow AverageLow
Kelly Mayden, MSN, FNP, AOCNP
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
Define key differences between chemical and biological drugs and biosimilar agents
Discuss the current history of the first approved biopharmaceuticals and similar biologic medicinal products
Recognize the key components of the Biologics Price Competition and Innovation Act of 2009
Describe the role of the advanced practitioner in the treatment of patients receiving biosimilar agents
*
Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CE/CME activities in which I have participated in the last 12 months
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*